Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
FunPep Company Limited is a clinical-stage Japanese biotechnology company focused on developing peptide-based therapeutics, primarily targeting oncology and metabolic diseases. The company operates with no commercial revenue, relying entirely on R&D investment and clinical trial advancement to drive valuation. With negative gross margins of -618% and operating cash burn of $500M annually, the stock trades on pipeline milestones, regulatory approvals, and partnership announcements rather than traditional financial metrics.
FunPep operates as a clinical-stage biotech with no current revenue generation. The business model centers on advancing proprietary peptide-based drug candidates through clinical trials (Phase I/II/III) to either: (1) achieve regulatory approval and commercialize independently in Japan, (2) out-license assets to larger pharmaceutical partners for upfront payments, milestones, and royalties, or (3) become an acquisition target. The company's peptide platform technology aims to create differentiated therapeutics with improved efficacy and safety profiles versus existing treatments. Value creation depends entirely on clinical trial success rates, regulatory pathway navigation, and ability to secure partnerships or financing to sustain operations through commercialization.
Clinical trial data readouts (Phase I/II/III results) - positive efficacy/safety data can drive 50-200% single-day moves
Regulatory milestone announcements (IND filings, FDA/PMDA fast-track designations, approval decisions)
Strategic partnership or licensing deals with major pharma companies (upfront payments, milestone structures)
Financing events (equity raises, dilution concerns) - capital runway visibility critical given $500M annual burn
Competitive pipeline developments in peptide therapeutics or target indications
Japanese healthcare policy changes affecting drug pricing or reimbursement for novel biologics
Binary clinical trial outcomes - single Phase III failure can render company value near-zero given concentrated pipeline
Regulatory approval uncertainty in Japan (PMDA) and potential international markets - peptide therapeutics face evolving regulatory frameworks
Technological obsolescence risk - competing modalities (mRNA, gene therapy, antibody-drug conjugates) may offer superior efficacy in target indications
Japanese healthcare system pricing pressures - government cost containment initiatives could limit commercial potential even with approval
Large-cap pharma competition with vastly superior capital resources and clinical development infrastructure
Peptide platform competition from established players (Novo Nordisk, Eli Lilly in metabolic diseases; Bristol Myers Squibb in oncology)
Patent expiration risk and limited exclusivity windows for peptide-based drugs versus small molecules
Partnership dependency - inability to secure pharma partnerships forces capital-intensive independent development
Severe liquidity risk - $500M annual cash burn with no revenue creates 12-18 month capital runway assuming $600-900M cash position
Equity dilution risk - future financing rounds at depressed valuations (stock down 37% YoY) will significantly dilute existing shareholders
Going concern risk if clinical setbacks coincide with unfavorable equity market conditions preventing capital raises
No debt cushion - zero leverage means no alternative financing sources beyond equity or asset sales during distress
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations. R&D timelines, regulatory processes, and clinical trial execution proceed independently of economic cycles. However, financing availability (equity markets, VC funding) tightens during recessions, creating liquidity risk. Patient enrollment can slow marginally in severe downturns if healthcare access deteriorates, but this is secondary to scientific/regulatory drivers.
Rising interest rates negatively impact FunPep through two channels: (1) Valuation compression - pre-revenue biotechs are valued on discounted future cash flows 5-10+ years out, making them highly duration-sensitive. Higher discount rates significantly reduce NPV of pipeline assets. (2) Financing costs - while FunPep currently has zero debt, future capital raises become more expensive as risk-free rates rise and investors demand higher equity risk premiums. The 10-year Treasury yield directly affects biotech sector multiples.
Minimal direct credit exposure given zero debt and $500M cash burn funded through equity. However, credit market conditions indirectly affect financing availability - tighter credit spreads and risk-off environments make equity raises more dilutive or impossible, creating existential liquidity risk for cash-burning clinical assets.
growth - Pure speculative growth investors and biotech specialists willing to accept binary risk/reward profiles. The -14,511% net margin, zero revenue, and negative cash flow eliminate value and dividend investors entirely. Momentum traders participate around clinical catalysts. Institutional ownership likely dominated by healthcare-focused hedge funds and venture capital rather than broad index funds. The 1,163x P/S ratio reflects pure option value on pipeline success rather than any fundamental valuation anchor.
high - Clinical-stage biotechs exhibit extreme volatility with beta typically 1.5-2.5x market. Single-day moves of 30-50% common around data readouts. The -37% one-year return with -17% six-month and +7% three-month returns demonstrate high dispersion. Low float and institutional concentration amplify price swings. Implied volatility typically 60-100% for biotech options versus 15-20% for broad market.
